Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI

Autor: B. Heindl, Daniel J. Kerkman, Michael Ewers, Kaj Blennow, Ray Zinkowski, Niels Andreasen, Åsa K. Wallin, N. S. M. Schoonenboom, Femke H. Bouwman, Peter Schönknecht, Johannes Schröder, Stefan J. Teipel, Katharina Buerger, P. Scheltens, John DeBernardis, Harald Hampel

Publikováno v: Neurology, 69(24), 2205-2212. Lippincott Williams and Wilkins
Ewers, M, Buerger, K, Teipel, S J, Scheltens, P, Schröder, J, Zinkowski, R P, Bouwman, F H, Schönknecht, P, Schoonenboom, N S M, Andreasen, N, Wallin, A, DeBernardis, J F, Kerkman, D J, Heindl, B, Blennow, K & Hampel, H 2007, ' Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI ', Neurology, vol. 69, no. 24, pp. 2205-2212 . https://doi.org/10.1212/01.wnl.0000286944.22262.ff

Background: The measurement of hyperphosphorylated tau (p-tau) in CSF has been proposed as a biomarker candidate for the prediction of Alzheimer disease (AD) in patients with mild cognitive impairment (MCI). However, a standard quantitative criterion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71959364d83b1ef4b827e3d08f43aed6
https://doi.org/10.1212/01.wnl.0000286944.22262.ff

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

Autor: Philip Scheltens, Yolande A.L. Pijnenburg, Annemieke J.M. Rozemuller, Fransje E. Reesink, Marinus A. Blankenstein, N.A. Verwey, C.E. Teunissen, N. S. M. Schoonenboom, Maartje I. Kester, P. M. van de Ven, W.M. van der Flier

Publikováno v: Neurology, 78(1), 47-54. Lippincott Williams and Wilkins
Schoonenboom, N S M, Reesink, F E, Verwey, N A, Kester, M I, Teunissen, C E, van de Ven, P M, Pijnenburg, Y A L, Blankenstein, M A, Rozemuller, J M, Scheltens, P & van der Flier, W M 2012, ' Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. ', Neurology, vol. 78, no. 1, pp. 47-54 . https://doi.org/10.1212/WNL.0b013e31823ed0f0

To determine how amyloid β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels in CSF behave in a large cohort of patients with different types of dementia.Baseline CSF was collected from 512 patients with Alzheimer disease (AD) and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::997c501d3626c9d4bc4962fc1f3141fd
https://research.vumc.nl/en/publications/53a4c458-ae34-4493-ab2d-017a868432b2

Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders

Autor: Philip Scheltens, Evert J. van Elk, Femke H. Bouwman, Marinus A. Blankenstein, Wiesje M. van der Flier, N. S. M. Schoonenboom, Astrid Kok

Publikováno v: Clinical chemistry. 52(8)

Measuring protein concentrations in cerebrospinal fluid (CSF) has gained wide acceptance for the differential and early diagnosis of dementia (1)(2)(3). Longitudinal changes in CSF biomarkers such as β-amyloid1–42 (Aβ1–42) are of potential use

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01eb97a95df0152cb1b29b2ab090ae69
https://pubmed.ncbi.nlm.nih.gov/16873300

Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid

Autor: Gerard J. van Kamp, Yolande A.L. Pijnenburg, Hugo Vanderstichele, Philip Scheltens, Pankaj Mehta, N. S. M. Schoonenboom, Marinus A. Blankenstein, Cees Mulder

Publikováno v: Schoonenboom, N S M, Mulder, C, Vanderstichele, H, Pijnenburg, Y A L, Van Kamp, G J, Scheltens, P, Mehta, P D & Blankenstein, M A 2005, ' Differences and similarities between two frequently used assays for amyloid β42 in cerebrospinal fluid ', Clinical Chemistry, vol. 51, no. 6, pp. 1057-1060 . https://doi.org/10.1373/clinchem.2005.048629
Clinical Chemistry, 51(6), 1057-1060. Oxford University Press

Amyloid β 42 (Aβ 42) concentrations in cerebrospinal fluid (CSF) are used to identify Alzheimer disease (AD) (1), but reported concentrations differ among studies, as does diagnostic accuracy (2). These differences may relate to the patient and con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e31433265f59d8b9b2d023c993746f
https://pubmed.ncbi.nlm.nih.gov/15845801

Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations

Autor: Esther van Herpen, John C. van Swieten, Sonia M. Rosso, Yolande A.L. Pijnenburg, Philip Scheltens, Peter Heutink, N. S. M. Schoonenboom

Publikováno v: Archives of Neurology, 60, 1209-1213. American Medical Association
Rosso, S M, Van Herpen, E, Pijnenburg, Y A L, Schoonenboom, N S M, Scheltens, P, Heutink, P & Van Swieten, J C 2003, ' Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations ', Archives of Neurology, vol. 60, no. 9, pp. 1209-1213 . https://doi.org/10.1001/archneur.60.9.1209
Archives of Neurology, 60(9), 1209-1213. American Medical Association

Background: Frontotemporal dementia (FTD) is a pathologically heterogeneous group of presenile neurodegenerative disorders, with or without the deposition of hyperphosphorylated tau protein in affected brain regions. Mutations in the tau gene have be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1fea374cc9e5b4c916679df18969d55
https://pubmed.ncbi.nlm.nih.gov/12975285